Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has announced its upcoming participation in the Stifel 2025 Virtual Targeted Oncology Forum. CEO Michael A. Metzger and other management team members will engage in a fireside chat scheduled for Wednesday, April 9, 2025, at 10:30 a.m. ET. The event will be accessible via live webcast through the company's website investor section, with a replay option available for a time.

News Market Reaction – SNDX

+7.99%

+7.99% Session move

In the trading session that priced this news, SNDX gained 7.99%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET.

A live webcast of the fireside chat will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

When is Syndax Pharmaceuticals (SNDX) presenting at the Stifel 2025 Virtual Targeted Oncology Forum?

Syndax (SNDX) will present on Wednesday, April 9, 2025, at 10:30 a.m. ET.

Who will represent SNDX at the Stifel 2025 Virtual Oncology Forum?

CEO Michael A. Metzger and members of the Syndax management team will participate in a fireside chat.

How can investors watch SNDX's presentation at the Stifel 2025 Forum?

A live webcast will be available in the Investor section of www.syndax.com, with replay available for a time.

What type of company is SNDX and what is their focus?

SNDX is a commercial-stage biopharmaceutical company developing innovative cancer therapies.